FDA approves Barr's generic version of Kos' cholesterol drug

04/28/2005 | Bloomberg Businessweek

The FDA granted final approval for Barr Pharmaceuticals to market a generic version of Kos Pharmaceutical's cholesterol drug Niaspan. The approval follows a licensing agreement between the two companies to settle a patent dispute clearing the way for Barr to market its generic product while also paying royalties to Kos.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN